High Quality ARA-290 for Sale Online
ARA-290, a synthetic peptide mimicking erythropoietin (EPO), demonstrates potential therapeutic benefits in the realm of inflammation and nerve damage repair. It interacts with specific receptors on cells, hinting at its promising applications.
Despite its relatively simple chemical structure, ARA 290 exhibits potent biological activity, making it an intriguing subject of research in biomedical science.
Understanding ARA-290’s functionality requires acknowledging its origins and biomedical research history. This knowledge is essential for the interpretation of new findings regarding this compound in scientific research.
Action on Inflammation
The primary mechanism through which ARA 290 operates is by binding to innate repair receptor (IRR). When activated, IRR can help decrease inflammatory responses within the body.
Nerve Regeneration Facilitation
Besides controlling inflammation, ARA 290 has shown promise in aiding nerve recovery. Studies indicate that this compound could reduce neuropathic pain and improve nerve function.
In conclusion, ARA 290’s action hinges upon its ability to bind with IRRs and facilitate healing processes within the body; be it reducing harmful inflammations or speeding up neural repairs after injury.
Clinical Trials Involving ARA-290
Several clinical trials have tested the effectiveness and safety of ARA-290. One key study involved patients with sarcoidosis-related chronic pain, where subjects experienced a significant reduction in symptoms. The results suggest a potential role for ARA 290 in managing neuropathic pain.
In another trial involving type-2 diabetic subjects suffering from neuropathy, ARA 290 led to a marked improvement in neuropathic symptoms and metabolic control. This gives hope that it might help manage complications associated with diabetes.
More extensive studies are needed to confirm these findings and explore additional applications as these are research chemicals and are not approved by the FDA for human consumption.
Therapeutic Applications of ARA 290
Research has indicated that ARA 290, a manufactured peptide, could be beneficial in treating neuropathy. This condition is characterized by nerve damage which can lead to chronic pain and numbness. Studies suggest that ARA 290 could stimulate nerve regeneration and reduce inflammation.
The potential benefits of ARA 290 are not limited to neuropathy alone. The peptide has also been studied for its possible effects on sarcoidosis, an inflammatory disease affecting multiple organs in the body but primarily the lungs and lymph glands.
According to research data, patients treated with ARA 290 reported significant relief from persistent symptoms like fatigue and pain.
Side Effects and Safety Profile of ARA 290
The safety profile of ARA 290 has been carefully examined in several clinical trials. Mild headaches were the most common complaint, occurring in a small percentage of subjects. But these typically resolved on their own without needing further intervention.
Other less frequent reactions included fatigue and temporary injection site discomfort. Other adverse effects were not reported.
In terms of safety concerns, there have not been any severe adverse events directly linked to ARA 290 use so far. No significant toxicities or systemic complications were noted by researchers.
Further research is necessary to validate preliminary study findings.
Future Research Directions for ARA 290
ARA 290 holds promise in the field of medicine, but more exploration is needed. For instance, studies suggest its potential use in neuropathic pain management.
The peptide’s role in managing chronic diseases has also sparked interest among scientists worldwide. There are hints at its effectiveness against diabetic neuropathy; however, detailed trials have yet to affirm this claim and more studies must be conducted to validate preliminary findings.
In summary, future research should focus on exploring new areas where this exciting peptide could make a significant difference.
Data on our ARA-290 for sale
CAS Number: 1208243-50-8
Formula: C51H84N16O21
Sequence: ZEQLERALNSS
Molecular Weight: 1257.3 g/mol
Class: Nonerythropoietic Peptide
Storage: Keep refrigerated upon reconstitution.
- Lyophilized sample in sterile glass vial.
- Minimum 99% pure.
- 16mg ARA-290 per vial.
- Diluent and laboratory supplies not included.
This preparation is for in vitro laboratory research purposes only by licensed professionals and is not approved by the FDA for bodily introduction of any kind into humans or animals. ARA-290 is not a drug, food, supplement, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, supplement or cosmetic.
Where to Buy ARA 290
If you’re looking for a reliable place to buy ARA-290, look no further than Sports Technology Labs. They offer high-quality research chemicals that are third-party lab tested in the USA.
Sports Technology Labs goes above and beyond by validating their products with more than 98% purity. This provides reassurance that your purchase is of the highest quality and will be effective.
In addition, they provide updated Certificates of Analysis (COAs) on every batch of product. This means you can be confident in what you’re buying because each batch has been thoroughly checked and verified.
Purity Matters
The importance of purchasing pure compounds cannot be overstated. Impurities could lead to inaccurate research results or even safety concerns. So when we say Sports Technology Labs ensures >98% purity – we mean business.
Updated COA’s: Why They Matter?
An updated COA is like a seal of trustworthiness from the supplier. It verifies that the product meets its specifications and assures quality control was maintained during production – giving researchers complete confidence in their purchases at Sports Technology Labs.
FAQs Related to ARA-290
ARA 290 is a synthetic peptide, designed to mimic the effects of erythropoietin. It’s mainly used in experimental treatments for nerve regeneration and inflammation reduction.
ARA 290 may help sarcoidosis patients by reducing inflammation and neuropathic pain. Early clinical trials have shown promising results but more research needs to be done.
The “best” can vary based on individual circumstances, but ARA 290 has demonstrated potential in treating neuropathy due its anti-inflammatory properties and ability to promote nerve regeneration.
ARA-290 works by binding with certain receptors on cells, reducing inflammatory response while encouraging cell survival and repair. This makes it potentially useful in various therapeutic applications such as nerve damage treatment.
References:
1. Brines, M., Dunne, A. N., van Velzen, M., Proto, P. L., Ostenson, C. G., Kirk, R. I., Et al. & Dahan, A. (2014). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Molecular medicine, 20(1), 658-666.
2. Dahan, A., Dunne, A., Swartjes, M., Proto, P. L., Heij, L., Vogels, O., Et al. & Brines, M. (2013). ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular medicine, 19(1), 334-345.
3. Austin Precision Medicine. (2023, October 11). Peptides for pain. Retrieved from https://austinprecisionmedicine.com/post/peptides-for-pain
4. Red Bluff Daily News. (2023, August 18). A full guide to the ARA-290 peptides. Retrieved from https://www.redbluffdailynews.com/2023/08/18/a-full-guide-to-the-ara-290-peptides/
5. Al-Onaizi, M. A., Thériault, P., Lecordier, S., Prefontaine, P., Rivest, S., & ElAli, A. (2022). Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, Behavior, and Immunity, 99, 363-382.
6. van Velzen, M., Heij, L., Niesters, M., Cerami, A., Dunne, A., Dahan, A., & Brines, M. (2014). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert opinion on investigational drugs, 23(4), 541-550.
7. Niesters, M., Swartjes, M., Heij, L., Brines, M., Cerami, A., Dunne, A., Et al. & Dahan, A. (2013). The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain. Expert Opinion on Orphan Drugs, 1(1), 77-87.
8. Erbayraktar, Z., Erbayraktar, S., Yilmaz, O., Cerami, A., Coleman, T., & Brines, M. (2009). Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Molecular medicine, 15(7), 235-241.
